Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Juno Therapeutics Inc.
Headquarters: Seattle, WA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Sep 14, 2023
Management Tracks
DNAnexus names Laur as CEO
Plus: Ports now CSO at Cargo and updates from Protalix, Culture, 4D, DiaMedica, Likarda, Precise, Pixelgen and Oviva
BioCentury | Sep 9, 2023
Deals
CAR T collaborations: the next cross-border deal trend?
BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development
BioCentury | Apr 11, 2023
Management Tracks
Legend hires Koneru as CMO
Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more
BioCentury | Apr 10, 2023
Product Development
Williams, Meininger tasked with validating Sana’s platforms in the clinic
The ex-Codiak and Vertex execs bring translational and clinical expertise in new modalities
BioCentury | Apr 4, 2023
Finance
Newly launched Cure Ventures taking hands-on approach to company creation
Three co-founders with experience at other firms hope to seed about 20 companies with $350M first fund
BioCentury | Oct 11, 2022
Management Tracks
Where cell and gene therapy companies are finding management talent
Demand outstrips supply, pushing newcos to go outside the field, tap first-time leaders for the top jobs
BioCentury | Aug 11, 2022
Product Development
Complexity is the attraction: Steve Harr on the pull of cell and gene therapy
Sana CEO tells The BioCentury Show his approach to making a step difference in the field
BioCentury | May 4, 2022
Finance
Newcomer Catalio builds momentum with $381M biotech venture fund
Firm’s model attracts top academics for company creation
BioCentury | Mar 26, 2022
Emerging Company Profile
Affini-T: engineering T cells to target oncogenic drivers in solid tumors
With $175M in the bank, Fred Hutch spinout is adding synthetic biology switches to T cells to increase their tumor infiltration and persistence
BioCentury | Feb 17, 2022
Management Tracks
New leadership for Merck’s human health business
Plus new CEOs at Renibus and Indapta, updates from Milestone, Briacell and more
Items per page:
1 - 10 of 337